Uppsala Universitet

Uppsala Universitet, a Swedish state-controlled educational institution, conducts bioequivalence and pharmaceutical regulatory science research for the Food and Drug Administration as a prime contractor, and participates in National Institutes of Health-funded biomedical research projects as a sub-recipient under prime research institutions. The university operates as a prime on two definitive FDA contracts and holds federal grant sub-awards under major research centers; it does not hold federal contract vehicles and operates outside the U.S. federal set-aside framework.

Uppsala Universitet's customer base concentrates among civilian health research agencies. The Food and Drug Administration leads the portfolio with four awards and $2.1 million in combined potential value, followed by the National Institutes of Health and its subsidiary institutes (National Cancer Institute, National Heart Lung and Blood Institute) with six combined awards, and the Department of the Air Force with two awards. The top five customer agencies account for 62% of recent awards by count and 97% of combined potential value, indicating tight concentration around FDA and NIH research missions.

On the FDA side, the university holds a $499,922 definitive contract awarded on September 1, 2026, for robust clinical endpoint bioequivalence studies using model integrated evaluation approaches, running through August 31, 2028, and an earlier $527,318 definitive contract (awarded September 26, 2022) for model-integrated strategies for bioequivalence evaluation of drugs with high variability and long half-life. Both contracts support FDA regulatory science advancement in pharmaceutical product evaluation and operate under full-and-open competition with no set-aside designation. The Air Force has awarded two project grants: a November 15, 2024 grant for modeling guided defect engineering of high-entropy MXenes toward coating and shielding applications (completion November 14, 2026) and a June 18, 2024 project grant in chemistry research (completion September 17, 2024). On the sub-recipient side, Uppsala Universitet collaborates with St. Jude Children's Research Hospital on pineoblastoma disease modeling, with Portland State University on mitonuclear adaptation and mutation mapping, with The Broad Institute on type-2 diabetes effector transcript characterization, and with the University of Southern California on Huntingtin misfolding mechanisms.

Award activity is sparse and episodic: one award in 2022, five in 2024, one in 2025, and one in 2026, with only one award (potential value $500 thousand) reaching completion inside the next twenty-four months. Combined obligated dollars ($8.7 million) exceed combined potential value ($2.2 million) across the portfolio, indicating that several awards have been invoiced or amended upward beyond their initial ceiling values. SCI-reported invoicing shows $527 thousand across the federal services scope in FY2025 alone, with prior-year SCI records carrying zero invoiced revenue despite recorded FTE deployment, suggesting that Uppsala Universitet's earlier contracts were either research grants (not subject to SCI hourly-rate reporting) or structured under other billing mechanisms. The university functions primarily as a prime research institution (81% of awards by count) with minimal sub-recipient engagement, and does not operate as a subcontractor to other federal contractors on professional-services contracts.